Ashton Thomas Private Wealth LLC Decreases Holdings in Johnson & Johnson $JNJ

Ashton Thomas Private Wealth LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 48,458 shares of the company’s stock after selling 792 shares during the period. Ashton Thomas Private Wealth LLC’s holdings in Johnson & Johnson were worth $7,402,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. GFG Capital LLC acquired a new position in Johnson & Johnson in the 2nd quarter worth $35,000. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the 1st quarter worth $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the 1st quarter worth $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson in the 1st quarter worth $49,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in Johnson & Johnson in the 1st quarter worth $52,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Price Performance

JNJ opened at $190.38 on Monday. The firm has a market cap of $458.69 billion, a price-to-earnings ratio of 18.38, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $194.48. The company’s 50-day moving average price is $182.26 and its 200 day moving average price is $166.37. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio is 50.19%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Cowen restated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. Raymond James Financial upped their target price on shares of Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. Royal Bank Of Canada restated an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a research note on Friday, October 10th. The Goldman Sachs Group upped their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the company a “buy” rating in a research note on Thursday, October 9th. Finally, Loop Capital set a $190.00 target price on shares of Johnson & Johnson in a research note on Wednesday. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.